MIR-21 ON PROLIFERATION IN HEPATOMA HEPG2 CELLS

Xuesong Deng^*, Jun Cheng, Naiyang Zhan, Janwei Chen, Yongqiang Zhan, Yong Ni, CaiXian Liao

Department of Hepatobiliary Surgery, the First Affiliated Hospital of Shenzhen University, Health Science Center; Shenzhen Second People’s Hospital, Shenzhen 518035, PR China 

Objective: The purpose of this paper is to study the effect of miR-21 on the proliferation of HepG2 cells, and to explore a feasible method to cure primary liver cancer.

Method: HepG2 and miR-21 were injected into 20 mice. Under the condition of strict control of experimental variables, the survival rate of hepatocytes and the survival rate of mice were recorded in detail. The specific experimental results are obtained by MTT method.

Results: The results showed that miR-21 factor could effectively inhibit the proliferation of hepatoma cells. The survival rate of HepG2 cells in the experimental group decreased from 75% to 20% under the action of miR-21. Moreover, the survival rate of mice with cancer was significantly increased compared with the previous traditional treatment.

Conclusion: Inhibition of miR-21 expression is expected to become a new target for the treatment of tumours that are dependent on it. This experiment also proved that miR-21 can inhibit the proliferation of HepG2 cells; therefore, miR-21 can provide a new treatment for liver cancer patients.